Theravance Biopharma (TBPH) Change in Accured Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Change in Accured Expenses data on file, last reported at -$4.9 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$4.9 million, down 221.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $656000.0 (down 80.42% YoY), and the FY2025 annual result was $4.0 million, up 173.09% from the prior year.
• Change in Accured Expenses declined to -$4.9 million in Q1 2026 per TBPH's latest filing, from -$1.3 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $17.2 million in Q4 2022 and troughed at -$10.3 million in Q1 2022.
• A 5-year average of -$454764.7 and a median of -$791000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses jumped 2740.95% in 2022, then sank 221.47% in 2026.
• A 5-year view of Change in Accured Expenses shows it stood at $17.2 million in 2022, then slumped by 102.54% to -$438000.0 in 2023, then soared by 782.88% to $3.0 million in 2024, then sank by 142.63% to -$1.3 million in 2025, then sank by 281.73% to -$4.9 million in 2026.
• Business Quant data shows TBPH's Change in Accured Expenses at -$4.9 million in Q1 2026, -$1.3 million in Q4 2025, and $3.6 million in Q3 2025.